Equity Issuances

SmartKem, Inc. issued up to 23,251,960 shares of Common Stock of warrant to certain institutional investors.

“On March 30, 2026, SmartKem, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Preferred Stock Purchase Agreement") with certain institutional investors (collectively, the "Buyers"), including certain March Noteholders (as defined below) pursuant to which the Company agreed to issue and sell to the Buyers in a private placement (the “Private Placement”), at an initial closing, (i) 11,411.5 shares of the Company's newly designated Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), with a stated value of $1,000 per share, convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at an initial conversion price of $0.5812 per share, subject to adjustment as set forth in the Certificate of Designations (as defined below), and (ii) warrants to purchase up to 23,251,960 shares of Common Stock (the "Warrants").”

SmartKem, Inc. issued 11,411.5 shares of preferred stock to certain institutional investors.

“On March 30, 2026, SmartKem, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Preferred Stock Purchase Agreement") with certain institutional investors (collectively, the "Buyers"), including certain March Noteholders (as defined below) pursuant to which the Company agreed to issue and sell to the Buyers in a private placement (the “Private Placement”), at an initial closing, (i) 11,411.5 shares of the Company's newly designated Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), with a stated value of $1,000 per share, convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at an initial conversion price of $0.5812 per share, subject to adjustment as set forth in the Certificate of Designations (as defined below), and (ii) warrants to purchase up to 23,251,960 shares of Common Stock (the "Warrants").”

Steele Creek Capital Corp issued 6,010.844 shares of common stock to investors for $8.3183 per share.

“On March 2, 2026, the Company sold 6,010.844 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for an aggregate offering price of $50,000.00, and a per share purchase price of $8.3183.”

Marvell Technology, Inc. issued 2,000,000 shares of the Company’s Series A Convertible Preferred Stock of preferred stock to NVIDIA Corporation for aggregate purchase price of $2,000,000,000.00 in cash.

“On March 31, 2026, Marvell Technology, Inc. (the “Company”) completed the issuance and sale of 2,000,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.002 per share (the “Series A Preferred Stock”), to NVIDIA Corporation (“NVIDIA”), pursuant to a Securities Purchase Agreement, dated as of March 31, 2026 (the “Purchase Agreement”), between NVIDIA and the Company. The shares of Series A Preferred Stock were sold for an aggregate purchase price of $2,000,000,000.00 in cash”

Partners Group Lending Fund, LLC issued 62,507 Units of unit to accredited investors for $95,760.

“investors” within the meaning of Regulation D under the Securities Act. Unit Class Number of Units 1 Total Consideration Class I Units 326,371 $ 500,000 Class M Units 62,507 $ 95,760”

Partners Group Lending Fund, LLC issued 326,371 Units of unit to accredited investors for $500,000.

“to investors who are “accredited investors” within the meaning of Regulation D under the Securities Act. Unit Class Number of Units 1 Total Consideration Class I Units 326,371 $ 500,000 Class M Units 62,507 $ 95,760”

Fortress Private Lending Fund issued 1,672,638 of common stock to accredited investors for aggregate consideration of $40.1 million.

“During March 2026, Fortress Private Lending Fund (the “Company”) sold its Class I common shares of beneficial interest, par value $0.01 per share (the “Shares”) for aggregate consideration of $40.1 million. The number of Shares to be issued was finalized on March 27, 2026.”

CYABRA, INC. issued preferred stock.

“on March 26, 2026, the Company filed the Series A Convertible Preferred Stock Certificate of Designation (as corrected by the Certificate of Correction (the “Certificate of Correction”) filed with the State of Delaware on March 27, 2026, the “Series A Certificate of Designation”)”

CYABRA, INC. issued common stock to LifeSci and Ladenburg.

“The issuance of the LifeSci Advisor Shares and the Ladenburg Advisor Shares in connection with the financial advisory and investment banking services provided by LifeSci and Ladenburg”

CYABRA, INC. issued preferred stock to the Sponsor.

“shares of Holdings Series B Preferred Stock and Holdings Series C Preferred Stock issued to the Sponsor pursuant to the Sponsor Note”

CYABRA, INC. issued preferred stock to PIPE Investors.

“shares of Holdings Series B Preferred Stock issued to the PIPE Investors in the PIPE Investments”

Silver Point Private Credit Fund issued 784,629 of its unregistered common shares of beneficial interest of common stock for $26.88 per Share.

“Silver Point Private Credit Fund (the “Fund) issued and sold 784,629 of its unregistered common shares of beneficial interest, par value $0.01 per share (the “Shares”), for an aggregate offering price of $21,090,830, reflecting a purchase price of $26.88 per Share (with the final number of Shares being determined on March 25, 2026).”

Inflection Point Acquisition Corp. VI issued 7,400,000 Private Placement Warrants of warrant to Inflection Point Holdings VI LLC (Sponsor) and Cantor Fitzgerald & Co. (Representative) for $1.00 per Private Placement Warrant, generating gross proceeds of $7,400,000.

“On March 30, 2026, simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreements, the Company completed the private sale of an aggregate of 7,400,000 private placement warrants (the “ Private Placement Warrants ”) to the Sponsor and Representative at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds to the Company of $7,400,000.”

GeoVax Labs, Inc. issued an aggregate of up to 1,269,316 shares of the Company's common stock of warrant to Holders of Existing Warrants for exercise of Existing Warrants for cash at $1.36 per share, aggregate gross proceeds of approximately $863,000.

“which the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 634,658 shares of the Company’s common stock, at a reduced exercised price of $1.36 per share, in consideration for the Company’s agreement to issue new warrants (the “New Warrants”) to purchase an aggregate of up to 1,269,316 shares of the Company’s common stock”

Capstone Energy Plus, Inc. issued 3,333,334 shares of common stock to affiliated with Monarch Alternative Capital LP for $4.50 per share.

“purchase and sale of an aggregate of 3,333,334 shares (the “Preferred Investor Shares”) of the Company’s Common Stock at a price of $4.50 per share”

Capstone Energy Plus, Inc. issued 80,000 shares of preferred stock to affiliated with Monarch Alternative Capital LP for $80.0 million.

“per share, a newly designated class of the Company’s preferred stock that will have the rights, privileges and preferences described below, for an aggregate purchase price of $80.0 million and (ii) the purchase and sale of an aggregate of 3,333,334 shares (the “Preferred Investor Shares”) of the Company’s Common Stock at a price of $4.50 per share for an aggregate”

Lunai Bioworks Inc. issued an aggregate of 1,433,621 additional shares of common stock of warrant to three of the Company's holders of secured promissory notes for part of the debt exchange.

“common stock purchase warrants to acquire an aggregate of 1,433,621 additional shares of common stock (the “Warrants”)”

Lunai Bioworks Inc. issued an aggregate of 3,909,293 shares of common stock to three of the Company's holders of secured promissory notes for cancellation and extinguishment of an aggregate of $828,770.14 of outstanding principal and accrued interest.

“Pursuant to the Debt Exchange Agreements, the Holders agreed to cancel and extinguish an aggregate of $828,770.14 of outstanding principal and accrued interest owed under the Investor Notes in exchange for an aggregate of 3,909,293 shares of the Company’s common stock”

ARTELO BIOSCIENCES, INC. issued warrants to purchase 255,073 shares of common stock of warrant to designees of the Placement Agent (H.C. Wainwright & Co., LLC) for issuance to designees of the Placement Agent.

“In addition, the Company issued to designees of the Placement Agent warrants to purchase 255,073 shares of Common Stock at an exercise price of $4.3125 per share (the “Placement Agent Warrants”), which have the same terms as the Common Warrants other than the exercise price.”

ARTELO BIOSCIENCES, INC. issued warrants to purchase 6,376,814 shares of common stock of warrant to certain accredited investors for Each Share or, at the election of the Purchaser in lieu of Shares, each Pre-Funded Warrant, was issued and sold along with two Common Warrants.

“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”

ARTELO BIOSCIENCES, INC. issued pre-funded warrants to purchase 3,107,407 shares of common stock of warrant to certain accredited investors for $3.449 per Pre-Funded Warrant and two Common Warrants.

“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”

ARTELO BIOSCIENCES, INC. issued 81,000 shares of common stock of common stock to certain accredited investors for $3.45 per share.

“On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).”

OnKure Therapeutics, Inc. issued pre-funded warrants to purchase 9,430,959 shares of Common Stock of warrant to institutional accredited investors for $4.1499 per underlying Warrant Share.

“pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share”

OnKure Therapeutics, Inc. issued 26,713,636 shares of common stock to institutional accredited investors for $4.15 per Share.

“the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share”

Silver Point Specialty Lending Fund issued 359,066 of common stock for $10,000,000 aggregate, $27.85 per share.

“As of March 2, 2026, Silver Point Specialty Lending Fund (the “Fund”) issued and sold 359,066 of its unregistered common shares of beneficial interest, par value $0.001 per share (the “Shares”), for an aggregate offering price of $10,000,000, reflecting a purchase price of $27.85 per Share (with the final number of Shares being determined on March 24, 2026).”

Liberty Energy Inc. issued convertible note to several investment banks acting as initial purchasers (collectively, the "Initial Purchasers") for $475.0 million aggregate principal amount.

“On March 30, 2026, Liberty Energy Inc. (the " Company ") completed its previously announced private offering of $475.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the " Notes ") to several investment banks acting as initial purchasers (collectively, the " Initial Purchasers ").”

Aprea Therapeutics, Inc. issued Pre-Funded Warrant Shares of common stock to certain accredited investors for expected gross proceeds of the Private Placement are approximately $30 million.

“occur on March 31, 2026, subject to satisfaction of customary closing conditions (the “ Closing Date ”). The expected gross proceeds of the Private Placement are approximately $30 million, before deducting the placement agent fees and estimated offering expenses payable by the Company. The Common Warrants will be exercisable immediately until December 31, 2029”

Aprea Therapeutics, Inc. issued up to approximately 37.2 million shares of warrant to certain accredited investors for purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price.

“shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares”

Edible Garden AG Inc issued 670,199 shares of common stock to Streeterville Capital, LLC for aggregate stated value of $1,184,000.

“Stock”), for a total of 670,199 shares of the Company’s common stock, par value $0.0001 per share (“Exchange Shares”). The Preferred Stock had an aggregate stated value of $1,184,000 (the “Stated Value”), or $1,000 per share. The number of Exchange Shares issued under the Exchange Agreements was determined by dividing the Stated Value by the Nasdaq Minimum”

Connect Biopharma Holdings Ltd issued 6,130,000 shares of common stock to institutional accredited investors for $3.25 per Share.

“On March 29, 2026, Connect Biopharma Holdings Limited (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with the purchasers named therein (the "Purchasers"), for the private placement (the "Private Placement") of 6,130,000 shares (the "Shares") of the Company's ordinary shares, par value $0.000174 per share (the "Ordinary Shares"), at a price of $3.25 per Share with respect to any Purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company.”

Perfect Moment Ltd. issued not specified of warrant to Krane Capital, LLC for pursuant to the SPA.

“the Shares and Krane Warrants to be issued to Krane Capital pursuant to the SPA as set forth under Item 1.01 of this report is incorporated herein by reference under this Item 3.02.”

Perfect Moment Ltd. issued not specified of common stock to Krane Capital, LLC for pursuant to the SPA.

“the Shares and Krane Warrants to be issued to Krane Capital pursuant to the SPA as set forth under Item 1.01 of this report is incorporated herein by reference under this Item 3.02.”

Perfect Moment Ltd. issued 1,864,753 shares of Common Stock of warrant to X3 Higher Moment Fund LLC for pursuant to the Loan Agreement.

“In connection with the Loan, the Company will issue to X3 warrants (the "X3 Warrants") to purchase 1,864,753 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at an exercise price of $0.46822 per share.”

Willow Tree Capital Corp issued approximately 1,711,263 common shares of beneficial interest of common stock for aggregate offering price of $27.5 million.

“On March 24, 2026, Willow Tree Capital Corporation (the “Company”) issued and sold approximately 1,711,263 common shares of beneficial interest (the “Shares”) of the Company for an aggregate offering price of $27.5 million.”

Nomadar Corp. issued up to 476,384 shares of Common Stock of common stock to an unaffiliated third-party accredited investor for $3.65 (the "Per Share Purchase Price").

“On March 27, 2026, Nomadar Corp., a Delaware corporation (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with an unaffiliated third-party accredited investor, pursuant to which the investor agreed to purchase, and the Company agreed to sell, up to $1.738 million (€1.5 million) of the Company’s class A common stock, par value $0.00001 per share (the “Common Stock”), in one or more closings, at a price per share equal to $3.65 (the “Per Share Purchase Price”), representing the issuance of up to 476,384 shares of Common Stock”

PRECISION OPTICS CORPORATION, INC. issued 159,722 shares of Company common stock of warrant to Lucid Capital Markets, LLC for $4.21 per share.

“in the aggregate, and the Company also issued to the Underwriter (or its designees) warrants to purchase up to 159,722 shares of Company common stock with an exercise price of $4.21 per share (the “Representative’s Warrant”). The Representative’s Warrants are exercisable at any time on or after March 30, 2026 and will terminate on March 27, 2031. The”

PRECISION OPTICS CORPORATION, INC. issued 2,777,777 shares of its common stock of common stock to Lucid Capital Markets, LLC for $3.60 per share.

“LLC (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 2,777,777 shares of its common stock, par value $0.01 per share, at a price to the public of $3.60 per share. In connection with the Offering, the Company has granted the Underwriter a 45-day over-allotment option to purchase up to an additional 416,667 shares of the Company’s”

SOCKET MOBILE, INC. issued convertible note to accredited investors for $500,000.

“Socket Mobile, Inc. (the “Company”) completed a secured subordinated convertible note financing of $500,000 (the “Financing”).”

PetVivo Holdings, Inc. issued 1,250,000 units of unit to accredited investor for $0.80 per Unit.

“PetVivo Holdings, Inc., including its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc. (collectively, the "Company," "we," and "us"), entered into a Subscription Agreement to receive One Million Dollars ($1,000,000) of equity financing in exchange for One Million Two Hundred Fifty Thousand (1,250,000) units of the Company (the "Units") at a purchase price of $0.80 per Unit (the "Offering").”

AMERICAN REBEL HOLDINGS INC issued 45,000 shares of common stock of common stock.

“On March 23, 2026, holders of 9,000 shares of Series D Convertible Preferred Stock converted such shares into 45,000 shares of common stock.”

Blue Owl Credit Income Corp. issued 2,268,562 of common stock to feeder vehicles primarily created to hold the Company’s Class I shares for $20,711,969.

“sold: Date of Unregistered Sale Approximate Number of Shares of Class I Common Stock Consideration As of March 2, 2026 (number of shares finalized on March 23, 2026) 2,268,562 $ 20,711,969”

Vor Biopharma Inc. issued 5,338,078 shares of common stock to TCGX for $14.05 per share.

“entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement.”

Blue Owl Technology Income Corp. issued 1,999,419 of common stock to feeder vehicles primarily created to hold the Company’s Class I shares for $ 19,934,210.

“sold: Date of Unregistered Sale Approximate Number of Shares of Class I Common Stock Consideration As of March 2, 2026 (number of shares finalized on March 23, 2026) 1,999,419 $ 19,934,210”

AB Commercial Real Estate Private Debt Fund, LLC issued unit to investors for $70,894,009.22 aggregate offering price.

“On March 25, 2026, AB Commercial Real Estate Private Debt Fund, LLC (the “Fund”) delivered a capital call notice to its investors relating to the Fund’s limited liability company units (the “Units”) for an aggregate offering price of $70,894,009.22.”

Maison Solutions Inc. issued common stock.

“On March 23, 2026, the Board determined, after reviewing the number of currently issued and outstanding shares of the Company, that it is in the best interests of the Company to effectuate a reverse stock split at a ratio of 1-for-10 (the “Reverse Stock Split”).”

Trio Petroleum Corp issued 446,149 restricted shares of common stock to McDermott Will & Schulte LLP for settlement of $392,700.23 in fees.

“and conditions set forth in the Settlement Agreement, the Company agreed to resolve, settle, and compromise among other things the Company’s obligation to pay an aggregate of $392,700.23 in fees for legal services previously performed by McDermott for the Company (the “Fees”). In consideration of the Fees, the Company agreed to issue to McDermott 446,149”

Fidelity Private Credit Fund issued 195,092 of common stock to feeder vehicles primarily created to hold the Fund’s Class I shares for $4,900,000.

“details the shares sold: Date of Unregistered Sale Amount of Class I Common Shares Consideration As of March 1, 2026 (number of shares finalized on March 23, 2026) 195,092 $ 4,900,000”

Lord Abbett Private Credit Fund issued 536,078 Common Shares of common stock to accredited investors for $13.3 million ($24.90 per share).

“As of March 2, 2026, Lord Abbett Private Credit Fund (“we”, the “Company” or the “Fund”) issued and sold approximately 536,078 of the Company’s common shares of beneficial interest (the “Common Shares”) for an aggregate offering price of approximately $13.3 million, reflecting a purchase price of $24.90 per Common Share (with the final number of Common Shares being determined on March 23, 2026).”

Blackstone Infrastructure Strategies L.P. issued 6,220,984 Class I units, 2,488,773 Class S units, 503,526 Class D units of unit to accredited investors and qualified purchasers for $259.9 million aggregate.

“On March 1, 2026, Blackstone Infrastructure Strategies L.P. (the “Fund”) sold unregistered limited partnership units (the “Units”) for aggregate consideration of approximately $259.9 million”

Lord Abbett Private Credit Fund S issued approximately 1,149,666 common shares of common stock to accredited investors for $24.87 per Common Share.

“As of March 2, 2026, Lord Abbett Private Credit Fund S (“we”, the “Company” or the “Fund”), issued and sold approximately 1,149,666 of the Company’s common shares of beneficial interest (the “Common Shares”) for an aggregate offering price of approximately $28.6 million, reflecting a purchase price of $24.87 per Common Share (with the final number of Common Shares being determined on March 23, 2026).”